High dose melphalan in the treatment of advanced neuroblastoma: Results of a randomised trial (ENSG‐1) by the European Neuroblastoma Study Group
Pediatric Blood & Cancer2004Vol. 44(4), pp. 348–357
Citations Over TimeTop 10% of 2004 papers
Abstract
In this trial, high dose melphalan improved the length of EFS and overall survival of children with stage IV neuroblastoma >1 year of age who achieved CR or GPR after OPEC induction therapy and surgery. Multi-agent myeloablative regimens are now widely used as consolidation therapy for children with stage IV disease and in those with other disease stages when the MYCN gene copy number in tumour cells is amplified. Because they are more toxic, complex, and costly these combination megatherapy regimens should be compared with single agent melphalan in randomised clinical trials.
Related Papers
- → Randomized Multicenter Trial of Hyperthermic Isolated Limb Perfusion With Melphalan Alone Compared With Melphalan Plus Tumor Necrosis Factor: American College of Surgeons Oncology Group Trial Z0020(2006)221 cited
- → Melphalan uptake, hyperthermic synergism and drug resistance in a human cell culture model for the isolated limb perfusion of melanoma(1994)45 cited
- → Factors influencing the chemosensitization of melphalan by misonidazole(1985)20 cited
- [Conservative therapy for retinoblastoma--effect of melphalan on in vitro electroretinogram].(1994)